IL220939A - Compounds that inhibit hdac and their pharmaceutical preparations - Google Patents
Compounds that inhibit hdac and their pharmaceutical preparationsInfo
- Publication number
- IL220939A IL220939A IL220939A IL22093912A IL220939A IL 220939 A IL220939 A IL 220939A IL 220939 A IL220939 A IL 220939A IL 22093912 A IL22093912 A IL 22093912A IL 220939 A IL220939 A IL 220939A
- Authority
- IL
- Israel
- Prior art keywords
- hdac
- inhibition
- compounds
- pharmaceutical compositions
- pharmaceutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29457510P | 2010-01-13 | 2010-01-13 | |
| PCT/US2011/021089 WO2011088181A1 (en) | 2010-01-13 | 2011-01-13 | Compounds and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL220939A0 IL220939A0 (en) | 2012-09-24 |
| IL220939A true IL220939A (en) | 2016-11-30 |
Family
ID=44304635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL220939A IL220939A (en) | 2010-01-13 | 2012-07-12 | Compounds that inhibit hdac and their pharmaceutical preparations |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8901156B2 (enExample) |
| EP (1) | EP2533783B8 (enExample) |
| JP (1) | JP6017313B2 (enExample) |
| KR (1) | KR101781663B1 (enExample) |
| CN (1) | CN103221047B (enExample) |
| AU (1) | AU2011205283B2 (enExample) |
| BR (1) | BR112012017441B1 (enExample) |
| CA (1) | CA2787018A1 (enExample) |
| EA (1) | EA022964B1 (enExample) |
| ES (1) | ES2560627T3 (enExample) |
| IL (1) | IL220939A (enExample) |
| MX (1) | MX341133B (enExample) |
| SG (1) | SG182401A1 (enExample) |
| WO (1) | WO2011088181A1 (enExample) |
| ZA (1) | ZA201205125B (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| EA201490228A1 (ru) * | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| WO2013066833A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| WO2013066835A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| CA2856334A1 (en) | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113778A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113791A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| IN2014DN07224A (enExample) | 2012-02-03 | 2015-04-24 | Basf Se | |
| CA2862354A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| KR20150046259A (ko) | 2012-08-23 | 2015-04-29 | 앨리오스 바이오파마 인크. | 파라믹소바이러스 바이러스성 감염의 치료용 화합물 |
| CN102826985B (zh) * | 2012-09-18 | 2015-08-19 | 厦门大学 | 一种1-(3,4,5-三羟基)苯基-1-烷基酮的制备方法 |
| EP2961746B1 (en) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| CN103214327A (zh) * | 2013-03-22 | 2013-07-24 | 郑州泰基鸿诺药物科技有限公司 | 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法 |
| CA2921294C (en) * | 2013-08-21 | 2023-05-16 | Alios Biopharma, Inc. | Antiviral compounds |
| KR101823488B1 (ko) | 2013-10-14 | 2018-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| PL226024B1 (pl) * | 2013-10-23 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Zastosowanie N-[2-[4-(4-metoksyfenylo)-1,3-tiazol-2-ilo]etylo]- -2-okso-2,5,6,7-tetrahydrocyklopenta[b] pirydyno-3-karboksyamidu |
| BR122021017872B1 (pt) * | 2014-06-06 | 2021-11-23 | Basf Se | Uso dos compostos, composição agroquímica e método para o combate dos fungos fitopatogênicos |
| EP3187497A4 (en) * | 2014-08-26 | 2018-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CA2961525A1 (en) | 2014-09-16 | 2016-03-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN104262281A (zh) * | 2014-10-16 | 2015-01-07 | 湖南华腾制药有限公司 | 一种2-溴-4(4-乙氧基苯基)恶唑的制备方法 |
| WO2016065583A1 (en) * | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Oxazole orexin receptor antagonists |
| US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| CU24411B1 (es) | 2014-12-09 | 2019-05-03 | Bayer Ag | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| TW201629026A (zh) | 2015-02-02 | 2016-08-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑的３－烷基雙環［４，５，０］異羥肟酸 |
| WO2016164770A1 (en) | 2015-04-10 | 2016-10-13 | Bioresponse, L.L.C. | Self-emulsifying formulations of dim-related indoles |
| EA035592B1 (ru) | 2015-05-07 | 2020-07-13 | Сиэйчдиай Фаундэйшн, Инк. | Ингибиторы деацетилаз гистонов и композиции и способы их применения |
| CA2984618C (en) | 2015-05-07 | 2024-01-09 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| US10357484B2 (en) | 2015-07-17 | 2019-07-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| HRP20230052T1 (hr) * | 2015-07-27 | 2023-03-03 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
| NZ739211A (en) * | 2015-07-27 | 2019-05-31 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| BR112017027798B1 (pt) | 2015-07-27 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| HRP20220003T1 (hr) * | 2015-08-04 | 2022-04-01 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
| WO2017033946A1 (ja) | 2015-08-25 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| PL3356358T3 (pl) | 2015-10-02 | 2020-11-02 | Syngenta Participations Ag | Mikrobiocydowe pochodne oksadiazolowe |
| US10501425B2 (en) | 2015-10-02 | 2019-12-10 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| FI3362445T3 (fi) * | 2015-10-12 | 2023-03-21 | Chong Kun Dang Pharmaceutical Corp | Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus |
| EP3167716A1 (en) | 2015-11-10 | 2017-05-17 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| AR106679A1 (es) | 2015-11-13 | 2018-02-07 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatógenos |
| EP3373735A1 (en) | 2015-11-13 | 2018-09-19 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| KR20180083419A (ko) | 2015-11-19 | 2018-07-20 | 바스프 에스이 | 식물병원성 진균을 퇴치하기 위한 치환 옥사디아졸 |
| CN108289448B (zh) | 2015-12-02 | 2021-10-22 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| KR20180088449A (ko) | 2015-12-03 | 2018-08-03 | 바스프 에스이 | 식물병원성 진균을 퇴치하기 위한 치환 옥사디아졸 |
| WO2017108569A1 (en) | 2015-12-22 | 2017-06-29 | Syngenta Participations Ag | Pesticidally active pyrazole derivatives |
| UY37062A (es) | 2016-01-08 | 2017-08-31 | Syngenta Participations Ag | Derivados de aryl oxadiazol fungicidas |
| CN105503716A (zh) * | 2016-01-30 | 2016-04-20 | 天长市淳峰精细材料合成厂 | 一种2,6-二氰基吡啶的制备方法 |
| JP6970680B2 (ja) * | 2016-03-15 | 2021-11-24 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| WO2017162868A1 (en) | 2016-03-24 | 2017-09-28 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| US10986839B2 (en) | 2016-04-11 | 2021-04-27 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
| EP3475275B1 (en) | 2016-06-23 | 2024-04-10 | Merck Sharp & Dohme LLC | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| WO2017222950A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| AR109304A1 (es) | 2016-08-10 | 2018-11-21 | Sumitomo Chemical Co | Compuesto de oxadiazol y su uso |
| WO2018057933A1 (en) * | 2016-09-22 | 2018-03-29 | The Regents Of The University Of Colorado, A Body Corporate | Compounds, compositions, and methods for reducing oxidative stress in cardiomyocytes |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| CA3055680A1 (en) | 2017-03-31 | 2018-10-04 | Syngenta Participations Ag | Fungicidal compositions |
| US10435399B2 (en) | 2017-07-31 | 2019-10-08 | Takeda Pharmaceutical Company Limited | HDAC6 inhibitory heterocyclic compound |
| CN112351981A (zh) | 2018-06-29 | 2021-02-09 | 先正达农作物保护股份公司 | 杀微生物的噁二唑衍生物 |
| US12161639B2 (en) | 2018-07-17 | 2024-12-10 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating PACS1 and PACS2 syndromes |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2020032071A1 (ja) * | 2018-08-08 | 2020-02-13 | 日本農薬株式会社 | オキサジアゾリン化合物又はその塩類及び該化合物を含有する農園芸用殺菌剤並びにその使用方法 |
| AR118673A1 (es) | 2019-04-18 | 2021-10-20 | Syngenta Crop Protection Ag | Procedimiento para la preparación de derivados de oxadiazol microbiocidas |
| CN113874369B (zh) | 2019-05-31 | 2024-08-27 | 株式会社钟根堂 | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑高邻苯二甲酰亚胺衍生化合物及包含其的药物组合物 |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| CN110526878A (zh) * | 2019-09-16 | 2019-12-03 | 成都睿智化学研究有限公司 | 一种2-(噁唑基)乙胺的制备方法 |
| CN114846012B (zh) | 2019-09-27 | 2024-01-26 | 武田药品工业株式会社 | 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 |
| CN114616231A (zh) | 2019-11-07 | 2022-06-10 | 日本农药株式会社 | 噁二唑啉化合物或其盐类及含有该化合物的农园艺用杀菌剂、以及其使用方法 |
| CN112194620B (zh) * | 2020-12-04 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种2-乙基-4-氰基吡啶的制备方法 |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| MX2023014819A (es) | 2021-06-14 | 2024-03-21 | Scorpion Therapeutics Inc | Derivados de la urea que pueden ser utilizados para tratar el cancer. |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
| CN116253730B (zh) * | 2023-03-06 | 2025-09-02 | 浙江大学 | 一种靶向降解hdac7蛋白的protac类化合物及其制备方法与应用 |
| CN116354897B (zh) * | 2023-03-31 | 2024-10-15 | 华东师范大学 | 一种取代的1，2，4-三氮唑、吡啶及嘧啶衍生物及其在药物中的应用 |
| WO2026041663A1 (en) * | 2024-08-22 | 2026-02-26 | Breye Therapeutics Aps | P2x7 receptor antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523312A (en) | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
| ATE361316T1 (de) * | 1999-09-08 | 2007-05-15 | Sloan Kettering Inst Cancer | Kristallstruktur einer deacetylase und deren inhibitoren |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| WO2006061638A2 (en) * | 2004-12-10 | 2006-06-15 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Heterocycle derivatives as histone deacetylase (hdac) inhibitors |
| WO2006102645A1 (en) | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica, N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
| GB0603041D0 (en) * | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| JP2013517279A (ja) | 2010-01-13 | 2013-05-16 | テンペロ、ファーマシューティカルズ、インコーポレイテッド | 化合物及び方法 |
| WO2013006408A1 (en) | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EA201490228A1 (ru) | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
-
2011
- 2011-01-13 KR KR1020127021121A patent/KR101781663B1/ko not_active Expired - Fee Related
- 2011-01-13 CA CA2787018A patent/CA2787018A1/en not_active Abandoned
- 2011-01-13 AU AU2011205283A patent/AU2011205283B2/en not_active Ceased
- 2011-01-13 EA EA201290638A patent/EA022964B1/ru not_active IP Right Cessation
- 2011-01-13 EP EP11733353.4A patent/EP2533783B8/en active Active
- 2011-01-13 MX MX2012008280A patent/MX341133B/es active IP Right Grant
- 2011-01-13 WO PCT/US2011/021089 patent/WO2011088181A1/en not_active Ceased
- 2011-01-13 US US13/522,044 patent/US8901156B2/en not_active Expired - Fee Related
- 2011-01-13 JP JP2012549064A patent/JP6017313B2/ja not_active Expired - Fee Related
- 2011-01-13 CN CN201180013827.0A patent/CN103221047B/zh not_active Expired - Fee Related
- 2011-01-13 ES ES11733353.4T patent/ES2560627T3/es active Active
- 2011-01-13 BR BR112012017441-0A patent/BR112012017441B1/pt not_active IP Right Cessation
- 2011-01-13 SG SG2012050076A patent/SG182401A1/en unknown
-
2012
- 2012-07-10 ZA ZA2012/05125A patent/ZA201205125B/en unknown
- 2012-07-12 IL IL220939A patent/IL220939A/en not_active IP Right Cessation
-
2014
- 2014-10-22 US US14/520,633 patent/US20150038534A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2560627T3 (es) | 2016-02-22 |
| BR112012017441B1 (pt) | 2019-11-19 |
| BR112012017441A2 (pt) | 2016-04-19 |
| US20130059883A1 (en) | 2013-03-07 |
| AU2011205283A1 (en) | 2012-08-02 |
| EP2533783B8 (en) | 2015-12-16 |
| KR101781663B1 (ko) | 2017-09-25 |
| EP2533783A1 (en) | 2012-12-19 |
| US20150038534A1 (en) | 2015-02-05 |
| EP2533783B1 (en) | 2015-11-04 |
| EP2533783A4 (en) | 2013-07-17 |
| WO2011088181A1 (en) | 2011-07-21 |
| CN103221047A (zh) | 2013-07-24 |
| CA2787018A1 (en) | 2011-07-21 |
| ZA201205125B (en) | 2013-03-27 |
| US8901156B2 (en) | 2014-12-02 |
| IL220939A0 (en) | 2012-09-24 |
| WO2011088181A9 (en) | 2013-01-31 |
| MX341133B (es) | 2016-08-08 |
| AU2011205283B2 (en) | 2014-07-10 |
| KR20130036093A (ko) | 2013-04-10 |
| CN103221047B (zh) | 2014-12-17 |
| JP2013517278A (ja) | 2013-05-16 |
| MX2012008280A (es) | 2012-11-23 |
| SG182401A1 (en) | 2012-08-30 |
| JP6017313B2 (ja) | 2016-10-26 |
| EA201290638A1 (ru) | 2013-02-28 |
| EA022964B1 (ru) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2533783B8 (en) | COMPOUNDS AND METHODS for the inhibition of HDAC | |
| ZA201301329B (en) | Novel compounds and compositions for the inhibition of nampt | |
| PT2538785T (pt) | Processos para a síntese de compostos de diariltiohidantoína e diarilhidantoína | |
| IL223535A (en) | Solid medicinal compositions | |
| LT3378862T (lt) | Dihidropirimidinoizochinolinonai ir jų farmacinės kompozicijos, skirti išsėtinės sklerozės gydymui | |
| IL224976A (en) | Converted history of 1h - indazole and a pharmaceutical preparation containing them | |
| EP2771321A4 (en) | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
| LT2616076T (lt) | Farmacinės kompozicijos | |
| ZA201300388B (en) | Compositions and methods for inhibition of the jak pathway | |
| IL251083A0 (en) | Compounds and preparations for the treatment of cancer | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| SI2605764T1 (sl) | Sestavki za zdravljenje raka | |
| ZA201207375B (en) | Stabilized pharmaceutical composition | |
| PL2391353T3 (pl) | Kompozycje farmaceutyczne trimetazydyny | |
| HUE039724T2 (hu) | Injekciós gyógyszerészeti készítmények ízületek kezeléséhez | |
| IL226554A (en) | Medicinal preparations containing alisporiovir | |
| PL2471520T3 (pl) | Kompozycja farmaceutyczna lewetyracetamu | |
| EP2560678A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| GB0902648D0 (en) | Pharmaceutical compounds and compositions | |
| GB0908317D0 (en) | Pharmaceutical compounds and compositions | |
| HU1000559D0 (en) | Pharmaceutical compositions for the treatment of osteoporosis and cancer | |
| GB0908069D0 (en) | Pharmaceutical compounds and compositions | |
| GB0919055D0 (en) | Pharmaceutical compounds and compositions | |
| GB0902651D0 (en) | Pharmaceutical compounds and compositions | |
| GB0903945D0 (en) | Pharmaceutical compounds and compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |